Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort

BMC Gastroenterology

Volumn 15, Issue 1, 2015, Pages

  Steinebrunner, Niels ^a   Sprinzl, Martin F ^b   Zimmermann, Tim ^b   Wörns, Marcus A ^b   Zimmerer, Thomas ^c   Galle, Peter R ^b   Stremmel, Wolfgang ^a   Eisenbach, Christoph ^a   Stein, Kerstin ^d   Antoni, Christoph ^c   Schattenberg, Jörn M ^b   Pathil, Anita ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE PSYCHOSIS; ADULT; AGED; AGGRESSION; ANEMIA; ARTICLE; CHRONIC HEPATITIS C; COMBINATION CHEMOTHERAPY; DECREASED APPETITE; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; GERMANY; HAIR LOSS; HASHIMOTO DISEASE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INSOMNIA; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRURITUS; RASH; RELAPSE; SUSTAINED VIROLOGICAL RESPONSE; TERTIARY HEALTH CARE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THRUSH; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; RETREATMENT; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETREATMENT; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84938676111     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-015-0328-9     Document Type: Article

References (25)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
2. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48(1):148-62.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9(4):331-8.
4. Verna EC, Brown Jr RS. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2006;10(4):919-40.
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-50.
6. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337-47.
7. Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, et al. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010;54(8):3187-96.
8. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.
9. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77.
10. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100-7.
11. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012;56(2):320-5.
12. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46(1):37-47.
13. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61(2):373-95.
14. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87.
15. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol. 2013;58(3):583-92.
16. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369(7):678-9.
17. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353-61.
18. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804-11.
19. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001.
20. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-8.
21. Schonning K. Comparison of the QIAGEN artus HCV QS-RGQ test with the Roche COBAS Ampliprep/COBAS TaqMan HCV test v2.0 for the quantification of HCV-RNA in plasma samples. J Clin Virol. 2014;60(4):323-7.
22. Sarrazin C, Dierynck I, Cloherty G, Ghys A, Janssen K, Luo D, et al. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay. J Clin Microbiol. 2015;53(4):1264-9.
23. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
24. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100-4.
25. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014;105:64-71.